NovoTTF-100L and pemetrexed + cisplatin/carboplatin may help your patients with MPM live longer1

Efficacy outcomes

Learn more about median overall survival for NovoTTF-100L™ + chemo

Primary endpoint

Median overall survival (OS)
(95% CI 12.1-25.8) across all patients treated with NovoTTF-100L and pemetrexed + cisplatin/carboplatin

Learn more about median OS across histologies for NovoTTF-100L™ + chemo
Learn more about progression-free survival for NovoTTF-100L™ + chemo

Secondary endpoint

Median progression-free survival (PFS)
(95% CI 6.7-8.6) across all patients treated with NovoTTF-100L and pemetrexed + cisplatin/carboplatin

Learn more about survival rates for NovoTTF-100L™ + chemo

The overwhelming majority of patients treated with NovoTTF-100L and pemetrexed + cisplatin/carboplatin (97%) experienced a measurable disease control rate (n=72)*,†

Learn more about study results for NovoTTF-100L™ + chemo

NovoTTF-100L is FDA-approved as 1st-line therapy for patients with MPM1,2

*In patients with at least one follow-up CT scan performed.

Minimum follow-up of 12 months.

 

References: 1. NovoTTF-100L Instructions For Use for Unresectable Malignant Pleural Mesothelioma. Novocure 2019. 2. FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019.

Next: Safety summary
Back to top
Indications For Use
jump to isi

The NovoTTF-100L System is indicated for the treatment of adult patients with unresect…